These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35372034)

  • 21. Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.
    Śledzińska P; Bebyn M; Szczerba E; Furtak J; Harat M; Olszewska N; Kamińska K; Kowalewski J; Lewandowska MA
    Mol Diagn Ther; 2022 Nov; 26(6):699-713. PubMed ID: 36053463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.
    Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ
    J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
    Dubbink HJ; Atmodimedjo PN; van Marion R; Krol NMG; Riegman PHJ; Kros JM; van den Bent MJ; Dinjens WNM
    J Mol Diagn; 2016 Sep; 18(5):775-786. PubMed ID: 27461031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
    Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
    J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All-in-one bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma.
    Higa N; Akahane T; Kirishima M; Yonezawa H; Makino R; Uchida H; Yokoyama S; Takajo T; Otsuji R; Fujioka Y; Sangatsuda Y; Kuga D; Yamahata H; Hata N; Horie N; Kurosaki M; Yamamoto J; Yoshimoto K; Tanimoto A; Hanaya R
    Pathol Res Pract; 2024 Nov; 263():155598. PubMed ID: 39357189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
    Sonoda Y
    Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients.
    Daoud EV; Chkheidze R; Yell PC; Hatanpaa KJ; Raisanen JM; Cai C
    Clin Neuropathol; 2022; 41(1):35-40. PubMed ID: 34672256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of DNA methylation in adult diffuse gliomas.
    Aoki K; Natsume A
    Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology.
    Slocum CC; Park HJ; Baek I; Catalano J; Wells MT; Liechty B; Mathew S; Song W; Solomon JP; Pisapia DJ
    Acta Neuropathol Commun; 2022 Nov; 10(1):167. PubMed ID: 36397144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse astrocytoma with mosaic
    Morgan KM; Danish S; Xiong Z
    Intractable Rare Dis Res; 2022 Feb; 11(1):43-45. PubMed ID: 35261853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing.
    Kim T; Lee A; Ahn S; Park JS; Jeun SS; Lee YS
    Brain Tumor Res Treat; 2024 Jan; 12(1):23-39. PubMed ID: 38317486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Targeted Next-Generation Sequencing Panel to Genotype Gliomas.
    Guarnaccia M; Guarnaccia L; La Cognata V; Navone SE; Campanella R; Ampollini A; Locatelli M; Miozzo M; Marfia G; Cavallaro S
    Life (Basel); 2022 Jun; 12(7):. PubMed ID: 35888045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.